$63.44 -$0.44 (-0.7%)

04:00 PM EST on 11/07/19

Genomic Health, Inc. (NASDAQ:GHDX)

CAPS Rating: 4 out of 5

A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Current Price $63.44 Mkt Cap $2.5B
Open $63.88 P/E Ratio 0.00
Prev. Close $63.88 Div. (Yield) $0.00 (0.0%)
Daily Range $62.74 - $64.57 Volume 12,386,891
52-Wk Range $50.77 - $86.70 Avg. Daily Vol. 9

Caps

How do you think NASDAQ:GHDX will perform against the market?

Add Stock to CAPS Watchlist

All Players

309 Outperform
20 Underperform
 

All-Star Players

85 Outperform
5 Underperform
 

Wall Street

6 Outperform
2 Underperform
 

Top NASDAQ:GHDX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

FoolishDane (< 20)
Submitted November 20, 2012

A single treatment won't work for everyone, so there's definite promise in a company working to perfect tests so that individualized treatments may be prescribed. This would result in less frustration for the patient and his/her family and,… More

Dormin111ob (97.61)
Submitted July 14, 2010

Losing money. Long slide downward.

Recent Community Commentary

Read the most recent pitches from players about GHDX.

Recs

0
Member Avatar TMFBlacknGold (95.66) Submitted: 10/17/2018 11:25:30 AM : Outperform Start Price: $62.13 NASDAQ:GHDX Score: -11.52

Genomic Health is growing year-over-year revenue at a healthy clip every quarter and is finally profitable. That's a really nice combination for long-term investors looking to get into an important new area of medicine. Invitae is growing revenue faster, but still losing a lot of money (it hopes to replicate Genomic Health's success in the coming years). Myriad Genetics delivers higher levels of profits, but has struggled to replace revenue lost from the legacy business (although the acquisition in summer 2018 should help).

Recs

0
Member Avatar Horsemonkey (54.36) Submitted: 8/1/2018 12:11:03 AM : Outperform Start Price: $53.36 NASDAQ:GHDX Score: +7.07

Genomic Health makes cancer tests. The CEO Kim Popovits is well liked and respected. The company is selling more tests for different types and stages of cancer, and its revenue prospects continue to grow. This a small cap company at 1.8 billion so the growth story is just getting started for Genomic Health.

Recs

0
Member Avatar MaestroFool (84.28) Submitted: 6/14/2017 7:07:02 PM : Outperform Start Price: $28.13 NASDAQ:GHDX Score: +74.55

Genomics and personalized medicine are the future. Outperform for the next 5+ years.

Leaderboard

Find the members with the highest scoring picks in GHDX.

Score Leader

songjon101

songjon101 (53.00) Score: +462.73

The Score Leader is the player with the highest score across all their picks in GHDX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
ezMarty < 20 9/6/2006 Outperform 5Y $11.84 +435.81% +157.77% +278.04 0 Comment
o556 96.47 7/19/2010 Outperform 1Y $12.32 +414.94% +194.11% +220.82 0 Comment
mebrownj 66.78 7/22/2010 Outperform 5Y $12.41 +411.20% +190.61% +220.59 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. dkelleher83 33.30 9/18/2006 Outperform 5Y $13.44 +372.02% +153.44% +218.58 4 Comments
MickeyJerry < 20 10/9/2006 Outperform 1Y $13.77 +360.71% +147.81% +212.90 1 Comment
Frannah < 20 9/20/2006 Outperform 3M $13.68 +363.74% +151.12% +212.62 0 Comment
mattchesky 54.18 7/13/2010 Outperform 5Y $12.76 +397.18% +188.22% +208.96 0 Comment
tamvanta66 80.04 9/15/2006 Outperform 3Y $13.80 +359.71% +151.96% +207.75 0 Comment
genericstockguy 40.61 9/14/2006 Outperform 3Y $13.81 +359.38% +154.67% +204.71 1 Comment
ekrupnik < 20 10/5/2006 Outperform 3Y $14.06 +351.21% +147.74% +203.47 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GHDX.